Murine myeloid leukemia: in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes

K. Pavelić, M. Sirotković, M. Kopitar, J. Pavelić, S. Vuk-Pavlović

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Parenteral administration of sericystatin A, an intracellular leukocyte inhibitor of the proinsulin-splitting enzyme cathepsin B, prolongs the mean survival time of mice with insulin-dependent myeloid leukemia. Sericystatin A reduces the supranormal blood levels of substances detectable by insulin-specific radioimmunoassay in these animals; this effect is abolished by concomitant insulin administration. It is concluded that sericystatin A reduces tumor proliferation indirectly, i.e. by reducing circulating insulin levels.

Original languageEnglish (US)
Pages (from-to)123-126
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume19
Issue number1
DOIs
StatePublished - Jan 1983

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Murine myeloid leukemia: in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes'. Together they form a unique fingerprint.

  • Cite this